Archimed SAS

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Archimed SAS
CRD #290024
SEC #802-113873
CIK #
AUM
Employees
Fees
Minimum
Phone0033481113533
Address9 Rue Des Cuirassiers
Lyon, France
Source [IAPD] [Website] [LinkedIn]
Total AUM ($)
1.00.80.60.40.20.02010201520212027
Type Form D Funds Date Sold AUM
PE MED Bio 2026-03-31 156.1 M
PE MED Rise SLP 2026-03-31 28.9 M
PE MED Vet 2026-03-31 359.0 M
PE MPII COI Jeisys 2026-03-31 148.6 M
PE MPII COI Zimvie 2026-03-31 213.0 M
PE MED Access SLP 2025-03-24 185.5 M
PE MED Rise SLP 2025-03-24
PE MED III B [2024-03-19] 28.2 M 96.8 M
Filed 2020-08-14 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
PE MED Platform II B FPCI 2024-03-19 186.2 M
PE MED 1 2023-03-30 2.1 M
PE MED III A [2023-03-30] 100.9 M 363.6 M
Filed 2021-08-13 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
PE MED Platform II SLP 2023-03-30 2,507.6 M
PE Mpi-Coi-Carso SLP 2023-03-30 241.5 M
PE Mpi-Coi-Prollenium SLP [2023-03-30] 11.9 M 210.9 M
Filed 2022-02-01 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
PE Mpi-Coi- SUAN SLP [2023-03-30] 12.6 M 163.4 M
Filed 2022-02-01 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
PE MPII COI NMI SLP 2023-03-30 869.0 M
PE MED Platform I SLP B [2021-03-31] 73.7 M 1,357.8 M
Filed 2020-08-14 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Commission $736,711 · Revenue Decline to Disclose
PE Mpi-Coi-Namsa SLP 2021-03-31 256.4 M
PE Polymed 2021-03-31 11.4 M
PE MED II SLP [2018-07-20] 83.7 M 297.5 M
Filed 2018-04-06 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,405,000 · Remaining Indefinite · Duration One year or less · Commission $1,674,706 · Revenue Decline to Disclose
AUM Breakdown Accounts AUM ($)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 0 0.0
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 0 0.0
By Discretionary
Discretionary 0 0.0
Non-Discretionary 0 0.0
Total 0 0.0
By Non-United States Persons
Non-United States Persons 0.0
United States Persons 0.0
Total 0 0.0
Form D Directors Role # Filings # Firms 2011 - 2026
Archimed Sas Executive Officer 5 2
Med III GP Executive Officer 2 2
Med Platform II GP Executive Officer 2 1
Archimed Executive Officer 2 1
Firm Profile (Form ADV)
Fund TypesPrivate Equity
LEI9695008GS04QJBETA603
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com